LISTED BIOTECH STOCKS AFFECTED BY GEOPOLITICS
April 15, 2026
"Supply disruptions should remain limited for most biotech companies."
The return of volatility linked to the war in the Middle East caught up with listed biotechs in the first quarter of 2026. The rise in oil prices translated into a rise in interest rates, penalizing growth stocks. Outlooks remain positive, with the start of the year also marked by a rebound in IPOs and mergers and acquisitions.
The good run was short-lived. After a very strong 2025, marked by double-digit returns, listed biotechnology stocks were again buffeted in the first quarter of 2026, although the average performance remained p...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit.
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt.
Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum.
RELATED ARTICLES
GenoSafe Secures the Essential CLIA Certification
The French CRO specialized, among other things, in analyses for gene therapies can now analyze clinical samples coming from across the Atlantic.GenoSa
FDA: BLUEBERRY SPARKS FIRE-BREATHING VAPORS
We were worried about the FDA with arrivals (Vinay Prasad), departures (Richard Padzur, Vinay Prasad), reversals and returns (Vinay Prasad), then agai
Sub-Q Bionics, Adcytherix
WORLD(United States; Israel/medtech/lymphedema) - Sub-Q Bionics has raised $1.5M in pre-seed funding from the Mayo Clinic, Yeda (Weizmann), priva